ScreenPoint Medical develops AI technology that supports radiologists in the early detection and diagnosis of breast cancer.
AI systems crucial for improving healthcare Founded in 2014 as a spin-off from Radboud UMC, ScreenPoint had the pioneering achievement in 2018 of commercially launching deep learning technology for breast cancer detection on 2D and 3D mammograms, making it available as a medical device in both Europe and the USA. Today, ScreenPoint's AI software is used globally. In 2023 alone, over 2 million mammograms in more than 40 countries worldwide were analyzed using ScreenPoint's AI system. In the Swedish population screening, the software demonstrated its effectiveness, enabling doctors to detect 30% more cancer cases that would have been missed otherwise. With over 30 peer-reviewed publications on the use of its AI system across different countries, populations, and mammography devices, ScreenPoint Medical continues to build indisputable evidence that AI systems are essential for improving, personalizing, and managing the increasing workload in healthcare.
At ScreenPoint Medical, we are constantly pushing boundaries to enhance AI systems and make them more broadly applicable. We focus not only on improving our current AI systems with the latest technological developments and datasets but also on developing new systems to enhance support for other clinical modalities, applications, and integration into clinical practice. This effort aligns with our mission to provide women worldwide with affordable quality healthcare, to detect breast cancer earlier, improve patient outcomes, and minimize the impact of breast cancer.
ScreenPoint Medical is located in Nijmegen at the Mercator Science Park on the Radboud Campus.
Founders: Prof. Nico Karssemeijer, Sir John Michael Brady
Website: https://screenpoint-medical.com/
LinkedIn: ScreenPoint Medical on LinkedIn
